Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the best pharmaceutical stocks on this list.

TheFly reported on May 13 that Wells Fargo downgraded AMPH to Equal Weight from Overweight, with the price objective reduced to $19 from $30 in a revised research note. The updated view reflects greater uncertainty around the company’s revenue trajectory for 2026 and 2027, along with reduced confidence in its ability to meet its 2026 outlook. The note also highlighted concerns related to AMP-004, particularly the risk tied to its potential to achieve interchangeability status, which could influence longer-term competitive positioning and growth expectations.

On May 7, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported first-quarter 2026 results for the period ended March 31, 2026, with revenue of $171.2 million versus consensus estimates of $173.4 million. The company highlighted continued progress in strengthening its commercial base and core operations during the quarter. Key developments included the approval and launch of Ipratropium Bromide HFA, alongside broader pipeline advancement supporting long-term strategic growth.

Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19

Management also pointed to an expanded product portfolio through an exclusive licensing agreement for a fully synthetic corticotropin compound. The company emphasized ongoing investment in proprietary pipeline assets and internal capabilities aimed at sustaining long-term expansion and operational resilience.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops, manufactures, and markets complex generic and proprietary injectable, inhalation, and intranasal drugs, mainly serving hospital and emergency care markets.

While we acknowledge the risk and potential of AMPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMPH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1